NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
77
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.60 | 7.00 | -0.08% |
| CAC 40 | 8,126.33 | 43.76 | -0.54% |
| DAX 40 | 23,588.99 | 287.56 | -1.20% |
| Dow JONES (US) | 47,055.31 | 401.91 | -0.85% |
| FTSE 100 | 9,687.94 | 10.43 | -0.11% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,883.94 | 16.65 | -0.07% |
| Nikkei 225 | 50,323.91 | 52.62 | -0.10% |
| NZX 50 Index | 13,459.15 | 5.31 | -0.04% |
| S&P 500 | 6,723.72 | 10.39 | -0.15% |
| S&P/ASX 200 | 8,571.80 | 7.00 | -0.08% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |